多発性硬化症(MS)の世界市場インサイト・疫学分析・市場予測

◆英語タイトル:Multiple Sclerosis Market Insight, Epidemiology and Market Forecast
◆商品コード:DELV803012
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年3月
◆ページ数:100
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後2営業日以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD6,250 ⇒換算¥687,500見積依頼/購入/質問フォーム
Site Price(同一事業所内共有可)USD12,500 ⇒換算¥1,375,000見積依頼/購入/質問フォーム
Enterprise Price(同一法人内共有可)USD18,750 ⇒換算¥2,062,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

DelveInsight’s ‘Multiple Sclerosis – Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Multiple Sclerosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Multiple Sclerosis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2016-2027

Multiple Sclerosis- Disease Understanding and Treatment Algorithm
The DelveInsight Multiple Sclerosis market report gives the thorough understanding of the Multiple Sclerosis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Multiple Sclerosis in the US, Europe, and Japan.

Multiple Sclerosis Epidemiology
The Multiple Sclerosis (MS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by Gender [male/female], age group [≤19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years, 70-79 years, and ≥80 years], sub-types [Relapsing Remitting MS, Primary Progressive MS and Progressive relapsing MS] and Expanded disability status scale (EDSS) [0.0-1.5, 2.0-3.5, 4.0-5.5, 6.0-7.5 and 8.0-9.5].
According to DelveInsight, the prevalent population of Multiple Sclerosis was estimated to be 1.98 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest MS Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. In United States, the peak prevalence has been observed in patients aged 45–49 years in both female and male participants.

Multiple Sclerosis Drug Chapters
This segment of the Multiple Sclerosis report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The drugs marketed for the treatment of mainly include disease-modifying therapies (DMT) – Copaxone , Tecfidera , Gilenya , Tysabri , Avonex, Aubagio , Lemtrada , Ocrevus , Rebif , Betaseron , Extavia , Plegridy , Fampyra , and Zinbryta . Detailed chapters for all of these drugs, along with the upcoming therapies i.e., [Siponimod (Novartis), Ponesimod (Johnson and Johnson), Ozanimod (Celgene), Ofatumumab (Novartis), Ublituximab (TG Therapeutics), ALKS 8700 (Alkermes Plc), and Mavenclad (Merck KgaA)] have been covered in the report.

Multiple Sclerosis Market Outlook
The Multiple Sclerosis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the global market of Multiple Sclerosis was estimated to be USD 21.25 billion in 2016, and is expected to increase at a CAGR of XX% from 2016-2027.

Multiple Sclerosis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The market size of Multiple Sclerosis includes the drug-uptake for individual therapies, which is further segmented on the basis of market size and market share by Line of therapy and Route of Administration.

Multiple Sclerosis Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Multiple Sclerosis Report Key Strengths
• 10 Year Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Drugs Uptake
• Highly Analyzed Market
• Key Cross Competition

Multiple Sclerosis Report Assessment
• Current Treatment Practices
• Unmet Needs
• Detailed Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Multiple Sclerosis market
• Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis market
• To understand the future market competition in the Multiple Sclerosis market.

【レポートの目次】

1. Report Introduction 1
2. Multiple Sclerosis Market Overview at a Glance 2
2.1. Market Share Distribution of Multiple Sclerosis in 2017 2
2.2. Market Share Distribution of Multiple Sclerosis in 2027 2
3. Disease Background and Overview: Multiple Sclerosis (MS) 13
3.1. Introduction 13
3.2. Risk Factors 16
3.3. Causes 17
3.4. Symptoms 18
3.5. Pathogenesis 20
3.6. Diagnosis 25
3.7. Expanded Disability Status Scale (EDSS) 29
4. Epidemiology and Patient Population 31
4.1. Key Findings 31
4.2. Population and Forecast Parameters 32
4.3. Prevalent Population of Multiple Sclerosis in 7MM 33
4.4. Prevalent Population of Multiple Sclerosis in 7MM – By Region 34
4.5. Prevalent Population of Multiple Sclerosis in 7MM – Distribution (2017) 35
4.6. Prevalent Population of Multiple Sclerosis in 7MM – Distribution (2027) 35
5. Epidemiology of Multiple Sclerosis 36
6. United States 36
6.1. Assumptions and Rationale 36
6.2. Prevalent Population of Multiple Sclerosis in United States 39
6.3. Sex-Specific Prevalence of Multiple Sclerosis in United States 40
6.4. Sub-type Specific Prevalence of Multiple Sclerosis in United States 41
6.5. Age-Specific Prevalence of Multiple Sclerosis in United States 42
6.6. Prevalence of Multiple Sclerosis based on EDSS Score in United States 43
7. Germany 44
7.1. Assumptions and Rationale 44
7.2. Prevalent Population of Multiple Sclerosis in Germany 46
7.3. Sex-Specific Prevalence of Multiple Sclerosis in Germany 47
7.4. Sub-type Specific Prevalence of Multiple Sclerosis in Germany 48
7.5. Age-Specific Prevalence of Multiple Sclerosis in Germany 49
7.6. Prevalence of Multiple Sclerosis based on EDSS Score in Germany 50
8. France 51
8.1. Assumptions and Rationale 51
8.2. Prevalent Population of Multiple Sclerosis in France 53
8.3. Sex-Specific Prevalence of Multiple Sclerosis in France 54
8.4. Sub-type Specific Prevalence of Multiple Sclerosis in France 55
8.5. Age-Specific Prevalence of Multiple Sclerosis in France 56
8.6. Prevalence of Multiple Sclerosis based on EDSS Score in France 57
9. Italy 58
9.1. Assumptions and Rationale 58
9.2. Prevalent Population of Multiple Sclerosis in Italy 60
9.3. Sex-Specific Prevalence of Multiple Sclerosis in Italy 61
9.4. Sub-type Specific Prevalence of Multiple Sclerosis in Italy 62
9.5. Age-Specific Prevalence of Multiple Sclerosis in Italy 63
9.6. Prevalence of Multiple Sclerosis based on EDSS Score in Italy 64
10. Spain 65
10.1. Assumptions and Rationale 65
10.2. Prevalent Population of Multiple Sclerosis in Spain 67
10.3. Sex-Specific Prevalence of Multiple Sclerosis in Spain 68
10.4. Sub-type Specific Prevalence of Multiple Sclerosis in Spain 69
10.5. Age-Specific Prevalence of Multiple Sclerosis in France 70
10.6. Prevalence of Multiple Sclerosis based on EDSS Score in Spain 71
11. United Kingdom 72
11.1. Assumptions and Rationale 72
11.2. Prevalent Population of Multiple Sclerosis in United Kingdom 74
11.3. Sex-Specific Prevalence of Multiple Sclerosis in United Kingdom 75
11.4. Sub-type Specific Prevalence of Multiple Sclerosis in United Kingdom 76
11.5. Age-Specific Prevalence of Multiple Sclerosis in United Kingdom 77
11.6. Prevalence of Multiple Sclerosis based on EDSS Score in United Kingdom 78
12. Japan 79
12.1. Assumptions and Rationale 79
12.2. Prevalent Population of Multiple Sclerosis in Japan 81
12.3. Sex-Specific Prevalence of Multiple Sclerosis in Japan 82
12.4. Sub-type Specific Prevalence of Multiple Sclerosis in Japan 83
12.5. Age-Specific Prevalence of Multiple Sclerosis in Japan 84
12.6. Prevalence of Multiple Sclerosis based on EDSS Score in Japan 85
13. Treatment Algorithm 86
13.1. Association of British Neurologists: Revised Guidelines for prescribing disease-modifying treatments in Multiple Sclerosis (2015) 93
13.2. Overcoming barriers in Progressive Multiple Sclerosis treatment 96
14. Unmet Needs 97
15. Marketed Drugs 99
16. Betaferon: Bayer Healthcare 99
16.1. Drug Description 99
16.2. Mechanism of Action 99
16.3. Regulatory Milestones 99
16.4. Advantages & Disadvantages 101
16.5. Safety and Efficacy 101
16.6. Product Profile 102
17. Rebif: Merck KGA 103
17.1. Drug Description 103
17.2. Mechanism of Action 103
17.3. Regulatory Milestones 103
17.4. Advantages & Disadvantages 104
17.5. Safety and Efficacy 104
17.6. Product Profile 105
18. Copaxone: Teva Pharmaceutical 106
18.1. Drug Description 106
18.2. Mechanism of action 106
18.3. Regulatory Milestones 106
18.4. Advantages & Disadvantages 108
18.5. Safety and Efficacy of Copaxone 108
18.6. Product Profile 109
19. Avonex: Biogen Idec. Limited 110
19.1. Drug Description 110
19.2. Mechanism of action 110
19.3. Regulatory Milestones 110
19.4. Advantages & Disadvantages 111
19.5. Safety and efficacy 111
19.6. Product Profile 112
20. Tysabri: Biogen Idec. Limited 113
20.1. Drug Description 113
20.2. Mechanism of action 113
20.3. Regulatory Milestones 113
20.4. Advantages & Disadvantages 115
20.5. Safety and efficacy of Tysabri 115
20.6. Product Profile 116
21. Fampyra/Ampyra: Acorda Therapeutics/ Biogen Idec Ltd. 117
21.1. Drug Description 117
21.2. Mechanism of action 117
21.3. Regulatory Milestones 117
21.4. Advantages & Disadvantages 118
21.5. Safety and efficacy of Ampyra 118
21.6. Product Profile 119
22. Gilenya: Novartis 120
22.1. Drug Description 120
22.2. Mechanism of action 120
22.3. Regulatory Milestones 120
22.4. Advantages & Disadvantages 121
22.5. Safety and efficacy of Gilenya 121
22.6. Product Profile 122
23. Aubagio: Genzyme 123
23.1. Drug Description 123
23.2. Mechanism of action 123
23.3. Regulatory Milestones 123
23.4. Advantages & Disadvantages 124
23.5. Safety and efficacy 124
23.6. Product Profile 125
24. Tecfidera: Biogen Idec Ltd. 126
24.1. Drug Description 126
24.2. Mechanism of action 126
24.3. Regulatory Milestones 126
24.4. Advantages & Disadvantages 127
24.5. Safety and efficacy 127
24.6. Product Profile 128
25. Plegridy: Biogen Idec Ltd. 129
25.1. Drug Description 129
25.2. Mechanism of action 129
25.3. Regulatory Milestones 129
25.4. Advantages & Disadvantages 130
25.5. Safety and efficacy 130
25.6. Product Profile 131
26. Lemtrada: Genzyme 132
26.1. Drug Description 132
26.2. Mechanism of action 132
26.3. Regulatory Milestones 132
26.4. Advantages & Disadvantages 133
26.5. Safety and efficacy 133
26.6. Product Profile 134
27. Zinbryta: Biogen Idec 135
27.1. Drug Description 135
27.2. Mechanism of action 135
27.3. Regulatory Milestones 135
27.4. Advantages & Disadvantages 135
27.5. Safety and efficacy 136
27.6. Product Profile 136
28. Ocrevus: Genentech 137
28.1. Drug Description 137
28.2. Mechanism of action 137
28.3. Regulatory Milestones 137
28.4. Advantages & Disadvantages 138
28.5. Safety and efficacy 138
28.6. Product Profile 139
29. Mavenclad: Merck 140
29.1. Drug Description 140
29.2. Mechanism of action 140
29.3. Regulatory Milestones 141
29.4. Safety and efficacy 141
29.5. Advantages & Disadvantages 142
29.6. Product Profile 142
30. Emerging Therapies 143
30.1. Key Cross Competition 143
30.2. Phase III Drugs 144
30.3. ALKS 8700: Biogen 144
30.3.1. Other development activities 144
30.3.2. Clinical Development 145
30.3.3. Clinical Trials Information 145
30.3.4. Safety and Efficacy 146
30.3.5. Advantages and Disadvantages 146
30.3.6. Product Profile 147
30.4. Ublituximab: TG Therapeutics 148
30.4.1. Other development activities 148
30.4.2. Clinical Development 149
30.4.3. Clinical Trials Information 150
30.4.4. Safety and Efficacy 150
30.4.5. Advantages and Disadvantages 151
30.4.6. Product Profile 151
30.5. Ozanimod: Celgene Corporation 152
30.5.1. Other development activities 152
30.5.2. Clinical Development 153
30.5.3. Clinical Trials Information 154
30.5.4. Safety and Efficacy 154
30.5.5. Advantages and Disadvantages 156
30.5.6. Product Profile 156
30.6. OMB157: Novartis 157
30.6.1. Other development activities 157
30.6.2. Clinical Development 158
30.6.3. Clinical Trials Information 158
30.6.4. Safety and Efficacy 159
30.6.5. Advantages and Disadvantages 160
30.6.6. Product Profile 160
30.7. MD1003: MedDay Pharma 161
30.7.1. Other development activities 161
30.7.2. Clinical Development 162
30.7.3. Clinical Trials Information 163
30.7.4. Safety and Efficacy 164
30.7.5. Advantages and Disadvantages 165
30.7.6. Product Profile 165
30.8. Masitinib: AB Science 166
30.8.1. Other regulatory milestone 166
30.8.2. Clinical Development 167
30.8.3. Clinical Trials Information 167
30.8.4. Safety and Efficacy 168
30.8.5. Advantages and Disadvantages 169
30.8.6. Product Profile 169
30.9. Siponimod: Novartis 170
30.9.1. Other development activities 170
30.9.2. Clinical Development 171
30.9.3. Clinical Trials Description 171
30.9.4. Safety and Efficacy 172
30.9.5. Advantages and Disadvantages 173
30.9.6. Product Profile 174
30.10. Ponesimod: Johnson & Johnson 175
30.10.1. Other regulatory milestones 175
30.10.2. Clinical Development 176
30.10.3. Clinical Trials Description 177
30.10.4. Safety and Efficacy 178
30.10.5. Advantages and Disadvantages 179
30.10.6. Product Profile 179
31. Global Market Size of Multiple Sclerosis (MS) 180
31.1. Global Market Size ($ MM) by Therapies 181
31.2. Global Market Share (%) by Line of Therapies 182
31.3. Global Market Size ($ MM) by Line of Therapies 183
31.4. Global Market Share of Therapies (%) by Route of Administration (RoA) 184
31.5. Global Market Size ($ MM) by Route of Administration (RoA) 185
32. United States 186
32.1. Market Size of Multiple Sclerosis in United States 186
32.2. Market Size by Therapies 192
33. EU5 193
33.1. Market Size of Multiple Sclerosis in EU5 193
33.2. Market Size of MS by Therapies in EU5 195
34. EU-5 broken down by countries
34.1. Market Size of MS in Germany 196
34.2. Market Size of MS in France 197
34.3. Market Size of MS in Italy 198
34.4. Market Size of MS in Spain 199
34.5. Market Size of MS in United Kingdom 200
35. Japan 201
35.1. Market Size of Multiple Sclerosis in Japan 201
35.2. Market Size by Therapies 203
36. Trends observed in MS therapies Cost in United States 204
37. Generic Competition in MS Market 206
38. Market Drivers 208
39. Market Barriers 210
40. Appendix 211
41. Report Methodology 211
41.1. Sources Used 211
42. Consulting Services 213
43. Disclaimer 214
44. About DelveInsight 214

Table 1: Expanded Disability Status Scale (EDSS) 29
Table 2: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027) 33
Table 3: Prevalent Population of Multiple Sclerosis in 7MM- By Region (2016-2027) 34
Table 4: Prevalent Population of Multiple Sclerosis in United States (2016-2027) 39
Table 5: Sex-Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 40
Table 6: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 41
Table 7: Age Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 42
Table 8: Prevalent Population of Multiple Sclerosis based on EDSS Score in United States (2016-2027) 43
Table 9: Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 46
Table 10: Sex-Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 47
Table 11: Sub-type Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 48
Table 12: Age Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 49
Table 13: Prevalent Population of Multiple Sclerosis based on EDSS Score in Germany (2016-2027) 50
Table 14: Prevalent Population of Multiple Sclerosis in France (2016-2027) 53
Table 15: Sex-Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 54
Table 16: Sub-type Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 55
Table 17: Age Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 56
Table 18: Prevalent Population of Multiple Sclerosis based on EDSS Score in France (2016-2027) 57
Table 19: Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 60
Table 20: Sex-Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 61
Table 21: Sub-type Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 62
Table 22: Age Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 63
Table 23: Prevalent Population of Multiple Sclerosis based on EDSS Score in Italy (2016-2027) 64
Table 24: Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 67
Table 25: Sex-Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 68
Table 26: Sub-type Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 69
Table 27: Age Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 70
Table 28: Prevalent Population of Multiple Sclerosis based on EDSS Score in Spain (2016-2027) 71
Table 29: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 74
Table 30: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 75
Table 31: Sub-type Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 76
Table 32: Age Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 77
Table 33: Prevalent Population of Multiple Sclerosis based on EDSS Score in United Kingdom (2016-2027) 78
Table 34: Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 81
Table 35: Sex-Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 82
Table 36: Sub-type Specific Prevalent Population of Multiple Sclerosis in Japan(2016-2027) 83
Table 37: Age Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 84
Table 38: Prevalent Population of Multiple Sclerosis based on EDSS Score in Japan (2016-2027) 85
Table 39:Medications for the treatment of MS 91
Table 40: Comparison of emerging drugs under development 143
Table 41: ALKS 8700 Clinical Trial Description, 2018 145
Table 42: Ublituximab, Clinical Trial Description, 2018 150
Table 43: RPC1063, Clinical Trial Description, 2018 154
Table 44: Ofatumumab, Clinical Trial Description, 2018 158
Table 45: MD1003, Clinical Trial Description, 2018 163
Table 46: Masitinib, Clinical Trial Description, 2018 167
Table 47: BAF312, Clinical Trial Description, 2018 171
Table 48: Ponesimod, Clinical Trial Description, 2018 177
Table 49: Global Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 180
Table 50: Global Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 181
Table 51: Global Market Share of Multiple Sclerosis (MS) by Line of Therapies in USD, Million (2017 & 2027) 182
Table 52: Global Market Size of Multiple Sclerosis (MS) by Line of Therapies in USD, Million (2017 & 2027) 183
Table 53: Global Market share of Multiple Sclerosis (MS) therapies by RoA in USD, Million (2017 & 2027) 184
Table 54: Global Market size of Multiple Sclerosis (MS) therapies by RoA in USD, Million (2017 & 2027) 185
Table 55: US Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 191
Table 56: US Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 192
Table 57: EU5 Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 194
Table 58: EU5 Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 195
Table 59: Germany Market Size of Multiple Sclerosis in USD, Million (2016-2027) 196
Table 60: France Market Size of Multiple Sclerosis in USD, Million (2016-2027) 197
Table 61: Italy Market Size of Multiple Sclerosis in USD, Million (2016-2027) 198
Table 62: Spain Market Size of Multiple Sclerosis in USD, Million (2016-2027) 199
Table 63: UK Market Size of Multiple Sclerosis in USD, Million (2016-2027) 200
Table 64: Japan Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 202
Table 65:Japan Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 203


Figure 1: Types of MS 14
Figure 2: Risk factors associated with MS 16
Figure 3: The immunological complexity of the immune/cytokine network in multiple sclerosis 21
Figure 4: Total Prevalent Population of Multiple Sclerosis in 7 MM (2016-2027) 33
Figure 5: Prevalent Population of Multiple Sclerosis in 7MM- By Region(2016-2027) 34
Figure 6: Prevalent Population of Multiple Sclerosis in United States (2016-2027) 39
Figure 7: Sex- Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 40
Figure 8: Sub-type Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 41
Figure 9: Age Specific Prevalent Population of Multiple Sclerosis in United States (2016-2027) 42
Figure 10: Prevalent Population of Multiple Sclerosis based on EDSS Score in US (2016-2027) 43
Figure 11: Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 46
Figure 12: Sex- Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 47
Figure 13: Sub-type Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 48
Figure 14: Age Specific Prevalent Population of Multiple Sclerosis in Germany (2016-2027) 49
Figure 15: Prevalent Population of Multiple Sclerosis based on EDSS Score in Germany (2016-2027) 50
Figure 16: Prevalent Population of Multiple Sclerosis in France (2016-2027) 53
Figure 17: Sex- Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 54
Figure 18: Sub-type Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 55
Figure 19: Age Specific Prevalent Population of Multiple Sclerosis in France (2016-2027) 56
Figure 20: Prevalent Population of Multiple Sclerosis based on EDSS Score in France (2016-2027) 57
Figure 21: Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 60
Figure 22: Sex- Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 61
Figure 23: Sub-type Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 62
Figure 24: Age Specific Prevalent Population of Multiple Sclerosis in Italy (2016-2027) 63
Figure 25: Prevalent Population of Multiple Sclerosis based on EDSS Score in Italy (2016-2027) 64
Figure 26: Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 67
Figure 27: Sex- Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 68
Figure 28: Sub-type Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 69
Figure 29: Age Specific Prevalent Population of Multiple Sclerosis in Spain (2016-2027) 70
Figure 30: Prevalent Population of Multiple Sclerosis based on EDSS Score in Spain (2016-2027) 71
Figure 31: Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 74
Figure 32: Sex- Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 75
Figure 33: Sub-type Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 76
Figure 34: Age Specific Prevalent Population of Multiple Sclerosis in United Kingdom (2016-2027) 77
Figure 35: Prevalent Population of Multiple Sclerosis based on EDSS Score in UK (2016-2027) 78
Figure 36: Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 81
Figure 37: Sex- Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 82
Figure 38: Sub-type Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 83
Figure 39: Age Specific Prevalent Population of Multiple Sclerosis in Japan (2016-2027) 84
Figure 40: Prevalent Population of Multiple Sclerosis based on EDSS Score in Japan (2016-2027) 85
Figure 41: Treatment algorithm for Multiple Sclerosis 87
Figure 42: Diagnosis and Therapy selection 92
Figure 43: Global Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 180
Figure 44: Global Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 181
Figure 45: Global Market Share of Multiple Sclerosis (MS) by Line of Therapies in USD, Million (2017 & 2027) 182
Figure 46: Global Market Size of Multiple Sclerosis (MS) by Line of Therapies in USD, Million (2017 & 2027) 183
Figure 47: Global Market share of Multiple Sclerosis (MS) therapies by RoA (2017 & 2027) 184
Figure 48: Global Market size of Multiple Sclerosis (MS) therapies by RoA in USD, Million (2017 & 2027) 185
Figure 49: US Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 191
Figure 50: US Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 192
Figure 51: EU5 Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 194
Figure 52: EU5 Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 195
Figure 53: Germany Market Size of Multiple Sclerosis in USD, Million (2016-2027) 196
Figure 54: France Market Size of Multiple Sclerosis in USD, Million (2016-2027) 197
Figure 55: Italy Market Size of Multiple Sclerosis in USD, Million (2016-2027) 198
Figure 56: Spain Market Size of Multiple Sclerosis in USD, Million (2016-2027) 199
Figure 57: UK Market Size of Multiple Sclerosis in USD, Million (2016-2027) 200
Figure 58: Japan Market Size of Multiple Sclerosis (MS) in USD, Million (2016-2027) 202
Figure 59: Japan Market Size of Multiple Sclerosis (MS) by Therapies in USD, Million (2016-2027) 203
Figure 60: Market Drivers 208
Figure 61:Market Barriers 210


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 多発性硬化症(MS)の世界市場インサイト・疫学分析・市場予測(Multiple Sclerosis Market Insight, Epidemiology and Market Forecast )]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆